Public Health authorities in Cuba’s third most populated city are carrying out a broad health intervention that, in addition to vulnerable sectors, prioritizes minors, and with this trial, 44 children in that age group will be vaccinated.

In statements to local media, Sonia Resik, the main researcher of Abdala studies in Cuba, assured that the trial will evaluate the safety and immunogenicity of the vaccine in children and teenagers, and the final results will be available in October.

The expert told the website of Adelante newspaper that ‘phase one will only seek the safety of the vaccine in this age group, for example, that no significant adverse reactions appear.’

The project, also called Ismaelillo, authorized by the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed), is being implemented in this region with Abdala, a vaccine that shows a 92.28 percent of efficacy.

The city, 540 kilometers east of Havana, adds a new age group to the vaccination process that began on June 28 with a health intervention in people over 60 years old.

jg/abo/mem/fam/gdc